Is Axsome Therapeutics Stock a Good Investment?
Axsome Therapeutics Investment Advice | AXSM |
- Examine Axsome Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Axsome Therapeutics' leadership team and their track record. Good management can help Axsome Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Axsome Therapeutics' business and its evolving consumer preferences.
- Compare Axsome Therapeutics' performance and market position to its competitors. Analyze how Axsome Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Axsome Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Axsome Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Axsome Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Axsome Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Axsome Therapeutics Stock
Researching Axsome Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 5.98. Axsome Therapeutics had not issued any dividends in recent years.
To determine if Axsome Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Axsome Therapeutics' research are outlined below:
| Axsome Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 352.39 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
Axsome Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Axsome Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Axsome Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Axsome Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.18 B.Axsome Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (0.74) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.52) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.52.Determining Axsome Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Axsome Therapeutics is a good buy. For example, gross profit margin measures Axsome Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Axsome Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Axsome Stock
As of the 24th of March, Axsome Therapeutics shows the Risk Adjusted Performance of 0.17, downside deviation of 2.16, and Mean Deviation of 2.57. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 129.17 per share. Given that Axsome Therapeutics has jensen alpha of 0.699, we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Axsome Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Axsome Therapeutics' Outstanding Corporate Bonds
Axsome Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Axsome Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Axsome bonds can be classified according to their maturity, which is the date when Axsome Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US05464HAB69 Corp BondUS05464HAB69 | View | |
| AXIS SPECIALTY FIN Corp BondUS05464HAC43 | View | |
| US05463HAB78 Corp BondUS05463HAB78 | View | |
| US05463HAC51 Corp BondUS05463HAC51 | View | |
| US05465CAA80 Corp BondUS05465CAA80 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Axsome Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Axsome Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.17 | |||
| Market Risk Adjusted Performance | (1.66) | |||
| Mean Deviation | 2.57 | |||
| Semi Deviation | 1.75 | |||
| Downside Deviation | 2.16 | |||
| Coefficient Of Variation | 556.09 | |||
| Standard Deviation | 4.03 | |||
| Variance | 16.24 | |||
| Information Ratio | 0.1864 | |||
| Jensen Alpha | 0.699 | |||
| Total Risk Alpha | 0.8776 | |||
| Sortino Ratio | 0.3483 | |||
| Treynor Ratio | (1.67) | |||
| Maximum Drawdown | 25.26 | |||
| Value At Risk | (3.42) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 4.65 | |||
| Semi Variance | 3.07 | |||
| Expected Short fall | (3.56) | |||
| Skewness | 2.46 | |||
| Kurtosis | 8.99 |
| Risk Adjusted Performance | 0.17 | |||
| Market Risk Adjusted Performance | (1.66) | |||
| Mean Deviation | 2.57 | |||
| Semi Deviation | 1.75 | |||
| Downside Deviation | 2.16 | |||
| Coefficient Of Variation | 556.09 | |||
| Standard Deviation | 4.03 | |||
| Variance | 16.24 | |||
| Information Ratio | 0.1864 | |||
| Jensen Alpha | 0.699 | |||
| Total Risk Alpha | 0.8776 | |||
| Sortino Ratio | 0.3483 | |||
| Treynor Ratio | (1.67) | |||
| Maximum Drawdown | 25.26 | |||
| Value At Risk | (3.42) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 4.65 | |||
| Semi Variance | 3.07 | |||
| Expected Short fall | (3.56) | |||
| Skewness | 2.46 | |||
| Kurtosis | 8.99 |
Consider Axsome Therapeutics' intraday indicators
Axsome Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Axsome Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 7936.5 | |||
| Daily Balance Of Power | 0.9154 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 128.3 | |||
| Day Typical Price | 128.59 | |||
| Price Action Indicator | 2.06 | |||
| Period Momentum Indicator | 2.38 |
Axsome Stock media impact
Far too much social signal, news, headlines, and media speculation about Axsome Therapeutics that are available to investors today. That information is available publicly through Axsome media outlets and privately through word of mouth or via Axsome internal channels. However, regardless of the origin, that massive amount of Axsome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Axsome Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Axsome Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Axsome Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Axsome Therapeutics alpha.
Axsome Therapeutics Corporate Management
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile |
Already Invested in Axsome Therapeutics?
The danger of trading Axsome Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Axsome Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Axsome Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Axsome Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Axsome Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.